This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by MacInnes, N. Articles by Harding, G. F. A. Search for Related Content PubMed PubMed Citation Articles by MacInnes, N. Articles by Harding, G. F. A. Social Bookmarking                         What's this?

Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms

Neurosciences Research Institute; Pharmaceutical Sciences Research Institute, Aston University, Birmingham, UK

S. L. Handley

Pharmaceutical Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, UK; S.L.Handley{at}aston.ac.uk

G. F. A. Harding

Neurosciences Research Institute Aston University, Birmingham, UK

Previous work has indicated recreational use of methylenedioxymethamphetamine (MDMA or ecstasy) is associated with elevated scores on self-report measures of depression. We sought to examine the long-term effects of consumption on depression in a group of individuals who had consumed large quantities of the drug in the past, but were now leading relatively drug free lives. Respondents to this study (n = 29) had consumed an average of 1.5 ecstasy tablets in the last month, 8.4 in the last 6 months and 23.3 in the last 12 months. The estimated total consumed was 527 tablets, indicating that these respondents were indeed former chronic users of the drug. None of the respondents had consumed ecstasy in the last 14 days. Levels of depression (Beck's Depression Inventory) were significantly (p < 0.01) elevated compared to a matched non-drug using control group. Within the group of former chronic users, these levels of depression were not significantly affected by current use of alcohol, cannabis or amphetamine, but were positively correlated with an external locus of control (p< 0.05), infrequent but severe- (p< 0.05) and frequent but mild- (p< 0.005) self-report measures of life stress. Multiple regression indicated that levels of frequent but mild life stress (p< 0.005) and the quantity of ecstasy tablets respondents consumed over a 12-h period (p< 0.05) were the only variables that were significant predictors of self-reported levels of depression. The results of this study indicate that former chronic ecstasy users report higher levels of depression than their matched controls.

Key Words: BDI • depression • ecstasy • former chronic • human • life stress • locus of control • MDMA • serotonin

Journal of Psychopharmacology, Vol. 15, No. 3, 181-186 (2001)
DOI: 10.1177/026988110101500310


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. Bedi, N. Van Dam, and J. Redman Ecstasy (MDMA) and high prevalence psychiatric symptomatology: somatic anxiety symptoms are associated with polydrug, not ecstasy, use J Psychopharmacol, February 1, 2010; 24(2): 233 - 240. [Abstract] [PDF]

				K Soar, A Parrott, and J Turner Attributions for psychobiological changes in ecstasy/MDMA and other polydrug users J Psychopharmacol, September 1, 2009; 23(7): 745 - 758. [Abstract] [PDF]

				R. S. Falck, Jichuan Wang, and R. G. Carlson Depressive symptomatology in young adults with a history of MDMA use: a longitudinal analysis J Psychopharmacol, January 1, 2008; 22(1): 47 - 54. [Abstract] [PDF]

				C. Guillot and D. Greenway Recreational ecstasy use and depression J Psychopharmacol, May 1, 2006; 20(3): 411 - 416. [Abstract] [PDF]

				A. C. Parrott MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress J Psychopharmacol, March 1, 2006; 20(2): 147 - 163. [Abstract] [PDF]

				R. Thomasius, P. Zapletalova, K. Petersen, R. Buchert, B. Andresen, L. Wartberg, B. Nebeling, and A. Schmoldt Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective J Psychopharmacol, March 1, 2006; 20(2): 211 - 225. [Abstract] [PDF]

				M. M. L. de Win, T. Schilt, L. Reneman, H. Vervaeke, G. Jager, S. Dijkink, J. Booij, and W. van den Brink Ecstasy use and self-reported depression, impulsivity, and sensation seeking: a prospective cohort study J Psychopharmacol, March 1, 2006; 20(2): 226 - 235. [Abstract] [PDF]

				J. P. Roiser, L. J. Cook, J. D. Cooper, D. C. Rubinsztein, and B. J. Sahakian Association of a Functional Polymorphism in the Serotonin Transporter Gene With Abnormal Emotional Processing in Ecstasy Users Am J Psychiatry, March 1, 2005; 162(3): 609 - 612. [Abstract] [Full Text] [PDF]

				A. C. Parrott Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy J Psychopharmacol, January 1, 2005; 19(1): 71 - 83. [Abstract] [PDF]

				H. R. Sumnall and J. C. Cole Self-reported depressive symptomatology in community samples of polysubstance misusers who report Ecstasy use: a meta-analysis J Psychopharmacol, January 1, 2005; 19(1): 84 - 92. [Abstract] [PDF]

				S. L. Verheyden, R. Maidment, and H. V. Curran Quitting Ecstasy: An Investigation of Why People Stop Taking the Drug and Their Subsequent Mental Health J Psychopharmacol, December 1, 2003; 17(4): 371 - 378. [Abstract] [PDF]

				N. MacInnes, S. L. Handley, and G. F.A. Harding The BDI of the beholder: an eye to experimental design J Psychopharmacol, May 1, 2002; 16(3): 273 - 273. [PDF]

				J. C. Cole and H. R. Sumnall The BDI of the beholder J Psychopharmacol, January 1, 2002; 16(1): 103 - 103. [PDF]